65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC

{"title":"65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC","authors":"S. Peters , D.S.W. Tan , D.E. Gerber , J. Urbanic , S.S. Ramalingam , J. Yu , L. Xing , A. Rittmeyer , T-E. Ciuleanu , J. Menezes , H.R. Kim , C.I. Rojas , K. Syrigos , H. Hayashi , A. Haridass , S. Bordenave , R. Nathani , G. Pudussery , L. Yang , D. De Ruysscher","doi":"10.1016/j.iotech.2024.100808","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100808"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-oncology technology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590018824001059","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}